GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

INOVIO Reports Inducement Grants Under Inducement Plan

news staff ~ 10/8/2024
PLYMOUTH MEETING , Pa. , Oct. 2 , 2024 /PRNewswire/ -- INOVIO ( NASDAQ : INO ) , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases , cancer , and infectious diseases , today announced that it has made

PLYMOUTH MEETING, Pa., Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the awards of restricted stock units ("RSU"s) covering an aggregate of 1,526 shares of common stock and options to purchase an aggregate of 1,600 shares of common stock, each with a grant date of September 30, 2024 (the "Grant Date"), to two newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The stock options have an exercise price of $5.78, the closing price of INOVIO's common stock on the Grant Date. The stock options will vest and become exercisable with respect to one-fourth of the shares underlying the stock options on the Grant Date, and an additional one-fourth of the shares underlying the stock options on the first, second, and third anniversaries of the Grant Date. The vesting of the RSUs and stock options will be subject to the employees' continued employment with INOVIO on the applicable vesting dates. Each of these awards is subject to the terms and conditions of a stock option agreement or RSU award agreement, as applicable, under the Inducement Plan.

About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

ContactsMedia: Jennie Willson, (267) 429-8567, [email protected]Investors: Thomas Hong, (267) 440-4298, [email protected]

SOURCE INOVIO Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3

440k+Newsrooms &Influencers icon1

9k+Digital MediaOutlets icon2

270k+JournalistsOpted In Originally published at https://www.prnewswire.com/news-releases/inovio-reports-inducement-grants-under-inducement-plan-302265897.html Images courtesy of https://pixabay.com

Photo by Gustavo Fring via Pexels

More from Medicine